Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
A phase 2 trial of Tarlatamab in small-cell lung cancer, run by Amgen, active and no longer recruiting.
Overview
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment is a phase 2 interventional study registered as NCT06502977 by Amgen, with 32 participants enrolled, started 2024-08-27 and due to reach its primary completion in 2025-03-28. Interventions recorded: Tarlatamab. Conditions listed: Extensive Stage Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
Shares Tarlatamab, Amgen, Small-cell lung cancer.
- TrialStudy Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Shares Tarlatamab, Amgen, Small-cell lung cancer.
- TrialA Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
Shares Tarlatamab, Amgen, Small-cell lung cancer.
- TrialPhase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
Shares Tarlatamab, Amgen, Small-cell lung cancer.
- TrialA Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small
Shares Tarlatamab, Amgen, Small-cell lung cancer.
- TrialA Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Shares Amgen, Small-cell lung cancer.
- TrialPharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
Shares Amgen, Small-cell lung cancer.
- TrialStudy Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
Shares Amgen, Small-cell lung cancer.